Dr. Jakubowiak on Minimal Residual Disease in Multiple Myeloma

Andrzej Jakubowiak, MD, PhD
Published: Wednesday, Sep 14, 2016



Andrzej Jakubowiak, MD, PhD, professor of Medicine, director, Myeloma Program, University of Chicago Medicine, discusses minimal residual disease (MRD) in multiple myeloma.

The combination of the proteasome inhibitor carfilzomib (Kyprolis) with lenalidomide (Revlimid) and dexamethasone demonstrated significant efficacy in a phase I and II studies in relapsed multiple myeloma.

Disease assessments were made with the use of the International Myeloma Working Group Uniform Response Criteria, with minimal response defined according to European Society for Blood and Marrow Transplantation criteria.


Andrzej Jakubowiak, MD, PhD, professor of Medicine, director, Myeloma Program, University of Chicago Medicine, discusses minimal residual disease (MRD) in multiple myeloma.

The combination of the proteasome inhibitor carfilzomib (Kyprolis) with lenalidomide (Revlimid) and dexamethasone demonstrated significant efficacy in a phase I and II studies in relapsed multiple myeloma.

Disease assessments were made with the use of the International Myeloma Working Group Uniform Response Criteria, with minimal response defined according to European Society for Blood and Marrow Transplantation criteria.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x